Novo Nordisk raises 2026 forecast on Wegovy pill success
The drugmaker says its Wegovy pill has passed five million prescriptions in the United States since its January launch.
Novo Nordisk has raised its financial forecast for 2026 following strong demand for the Wegovy pill, the tablet form of its weight-loss treatment launched in the United States in January.
The company now expects full-year adjusted sales growth and adjusted operating profit to both be down somewhere between zero and six percent — an improvement on its May 6 forecast, when it said both would fall by between four and 12%.
The tablet version of Wegovy has been a major success in the United States since its launch, and was recently approved for use in Europe.
"The Wegovy product portfolio remains a key growth driver for Novo Nordisk in 2026," president and chief executive Mike Doustdar said in a statement.
He cited "the continued rapid adoption of Wegovy pill in the US, which has reached more than five million prescriptions since its launch, alongside encouraging early uptake in markets outside the US".
In the second quarter, adjusted sales rose seven percent from a year earlier at constant exchange rates to 78.4 billion kroner (US$12 billion), while adjusted operating profit jumped 11% to 33.4 billion kroner.
The Danish drugmaker has been battling fierce competition in the anti-obesity treatment sector.
This article was produced with the assistance of artificial intelligence (AI), in accordance with our editorial policy.